Medical Therapeutics

OncoRx Pharmaceuticals, Inc.

Brief Description

OncoRx Pharmaceuticals is an early-stage pharmaceutical company discovering and developing targeted therapies that control the progression of invasive malignant cancer. OncoRx has identified and tested drugs that markedly alter the sustained directional mobility, the uncontrolled cell cycle, and t​​he unrestrained growth and proliferation of intrinsically and acquired therapy-resistant tumors. Unlike non-aggressive primary tumors, the growth, progression and invasiveness of therapy-resistant tumors are not effectively controlled with currently available cancer therapies...

Libraria, Inc.

Brief Description

Libraria Inc. is using computational techniques to discover new small-molecule drugs that can be administered orally. Its proprietary technology enables the company and its partners to leverage known molecular structures, chemistry protocols, and bioactivity data to speed the chemistry phase of drug discovery by up to 50%.

Timeline

2000. Company founded.

2003. Acquired by Eidogon-Sertanty.

Inventors Jonathan Ellman

Iris Micromedical, Inc.

Brief Description

Drug delivery based on microstructural devices that administer therapeutic agents to selected target sites for treatment.

Iris Micromedical was focused on the development of UC Berkeley Associate Professor of Engineering Mauro Ferrari's silicon particulate technology for the intravascular targeted treatment of cancer imedd.

Four years after founding Iris Micromedical, Dr. Ferrari moved to Ohio State University as a professor of bioengineering, internal medicine, and mechanical engineering, and reformed the company as IMedd, Inc.

Timeline 1995....

CalGen Therapeutics

Brief Description

Developer of a therapeutic inhaled antisense technology designed to prevent and treat respiratory infections.

Timeline 2021. Company founded Inventors

Kasper Karstensen, Sakari Kauppinen, Anders Michael Naar, Chi Zhu

Biotock

Brief Description

Development of treatments for age-related macular degeneration, a leading cause of blindness.

Timeline 2022. Company founded Inventors

Monika Maria Haoui, Polina Lishko

Apertor Pharmaceuticals

Brief Description

Apertor creates novel molecular glues for therapeutic applications in multiple disease areas. The company applies a world-class synthetic biology platform using non-model organisms, a deep knowledge of complex natural products relevant to human health, and a computational pipeline enabled by structure-guided design. The result is a first-in-class approach to solving important pharmacological problems and delivering new, high-value treatment options for patients. The company was co-founded by UC Berkeley Professor of Chemical & Biomolecular Engineering and of...

Chiron Corporation

Brief Description

Chiron Corporation was an American biotechnology company engaged in biopharmaceuticals, vaccines and blood testing.

Timeline 1981. Company founded 1990. Company Initial Public Offering on NASDAQ under the ticker symbol of CHIR. 2006. Acquired by Novartis Inventors

Henry Chang, Felix Karim, Gerald Rubin, Marc Therrien, David Wassarman

Cell-X

Brief Description

Editing T-cells with nanopore-electroporation to improve CRISPR-Cas9 editing capabilities.

Timeline 2021. Company founded Inventors

YuHong Cao, Jennifer Doudna, Enbo Ma, Peidong Yang

Epigenetic Gene Editing

Brief Description

Epigenetic Gene Editing is a gene editing tools company dedicated to improvements in CRISPR-Cas9 editing by providing a fusion protein kit to gene editing companies.

Formerly known as EPI-CRISPRx.

Timeline 2021. Company founded Inventors

Enrique Lin Shiao, Jennifer Doudna

Demetrix, Inc.

Brief Description

Demetrix, Inc. works with nature to make rare ingredients readily accessible to promote healthier and happier lives. By using microorganisms such as baker's yeast and fermentation combined with the most advanced biotechnology, data science and automation, Demetrix can produce complex, sustainable ingredients at high purity and low cost. The company is initially focusing on producing cannabinoids to build its portfolio of ingredients. Exclusively licensed breakthrough technology from the University of California, Berkeley will soon enable Demetrix to commercially produce...